Extended Data Fig. 3: ELOVL6i treatment alters the cellular lipid composition.
From: ELOVL6 activity attenuation induces mutant KRAS degradation
a, b, c, Untargeted lipidomic analysis of lipid species in G12V KRAS-expressing NCI-H727 control and ELOVL6i-treated cells after 1-week of treatment from three biological replicates. Data are shown as molar fractions of (a) glycerolipids, (b) sphingolipids, and (c) glycerophospholipids in total lipids detected. Statistical significance was determined by a two-tailed unpaired T-test. *P < 0.05, **P < 0.01, ***P < 0.001, data are represented as mean ± s.d. DAG: Diacylglycerol (P = 0.0036); TAG: Triacylglycerol (P = 0.0086); SM: Sphingomyelin (P = 0.0058); HexCer: Hexosylceramide (P = 0.0073); Cer: Ceramide (P = 0.37); CL: Cardiolipin (P = 0.026); PA: Phosphatidic acid (P = 0.024); PC: Phosphatidylcholine (P = 0.96); PE: Phosphatidylethanolamine (P = 0.022); PG: Phosphatidylglycerol (P = 0.0004); PI: Phosphatidylinositol (P = 0.003); PS: Phosphatidylserine (P = 0.0011).
